Cingulate publishes PK data for ADHD drug CTx-1301 in CNS Drugs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. KTOS

Go back to Cingulate publishes PK data for ADHD drug CTx-1301 in CNS Drugs

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

August 11, 2026 8:30 AM EDT

KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release (PTR) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs. The open-access manuscript provides clinicians and researchers with pharmacokinetic data supporting CTx-1301 (dexmethylphenidate HCl), Cingulate's lead product candidate for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Available through open access, the manuscript expands Cingulate's growing body of peer-reviewed evidence supporting CTx-1301 and follows the... More